Patents by Inventor Elsa Bianchini

Elsa Bianchini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutated antithrombins, a process for preparing the same and their use as drugs
    Patent number: 8822654
    Abstract: The present invention relates to the use of a composition including of at least a mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having no anticoagulant activity, for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: September 2, 2014
    Assignees: Universite Paris—Sud XI, Assistance Publique-Hopitaux de Paris, Universite Paris Descartes
    Inventors: Delphine Borgel, Véronique Ferger, Elsa Bianchini, Nicolas Lerolle, Jean-Luc René Diehl
  • Use of mutated antithrombins for treating or preventing coagulation disorders
    Patent number: 8741844
    Abstract: Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: June 3, 2014
    Assignee: Universite Paris-Sud XI
    Inventors: Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini
  • Thrombin cleavable factor X analogues
    Patent number: 8168753
    Abstract: The invention relates to factor X analogues containing the thrombin-cleavable sequence Pro-Arg-Ala in place of the-sequence Thr-Arg-Ile of the activation site of native factor X. These factor X analogues can be used to obtain procoagulant medicinal products.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: May 1, 2012
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Virginie Louvain, Elsa Bianchini, Pierre-Emmanuel Marque, Claire Calmel-Tareau, Martine Aiach, Bernard Le Bonniec
  • MUTATED ANTITHROMBINS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS DRUGS
    Publication number: 20120088715
    Abstract: The present invention relates to the use of a composition including of at least a mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having no anticoagulant activity, for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury.
    Type: Application
    Filed: January 15, 2010
    Publication date: April 12, 2012
    Applicants: UNIVERSITE PARIS-SUD XI, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini, Nicolas Lerolle, Rene Jean-Luc Diehl
  • USE OF MUTATED ANTITHROMBINS FOR TREATING OR PREVENTING COAGULATION DISORDERS
    Publication number: 20100298224
    Abstract: Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders.
    Type: Application
    Filed: July 18, 2008
    Publication date: November 25, 2010
    Applicant: UNIVERSITE PARIS-SUD XI
    Inventors: Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini
  • Thrombin-cleavable chimeric proteins
    Patent number: 7589178
    Abstract: The invention relates to chimeric proteins comprising an artificial sequence for cleavage by thrombin, in which the activation peptide is fibrinopeptide A. Preferably, said chimeric proteins are derived from the zymogen of a serine protease such as PC or FX, by replacing the activation peptide of said zymogen with fibrinopeptide A, or a portion thereof, comprising at least amino acids P10 to P1 of said fibrinopeptide.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: September 15, 2009
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard Le Bonniec, Pierre-Emmanuel Marque, Virginie Louvain, Claire Calmel, Elsa Bianchini, Martine Aiach
  • Thrombin cleavable factor x analogues
    Publication number: 20060148038
    Abstract: The invention relates to factor X analogues containing the thrombin-cleavable sequence Pro-Arg-Ala in place of the-sequence Thr-Arg-Ile of the activation site of native factor X. These factor X analogues can be used to obtain procoagulant medicinal products.
    Type: Application
    Filed: June 30, 2003
    Publication date: July 6, 2006
    Applicant: INST. NAT'L DE LA SANTE ET DE LA RECH. MEDICALE
    Inventors: Virginie Louvain, Elsa Bianchini, Pierre-Emmanuel Marque, Claire Calmel-Tareau, Martine Aiach, Bernard Le Bonniec
  • Thrombin-cleavable chimeric proteins
    Publication number: 20050202527
    Abstract: The invention relates to chimeric proteins comprising an artificial sequence for cleavage by thrombin, in which the activation peptide is fibrinopeptide A. Preferably, said chimeric proteins are derived from the zymogen of a serine protease such as PC or FX, by replacing the activation peptide of said zymogen with fibrinopeptide A, or a portion thereof, comprising at least amino acids P10 to P1 of said fibrinopeptide.
    Type: Application
    Filed: October 18, 2002
    Publication date: September 15, 2005
    Inventors: Bernard Le Bonniec, Pierre-Emmanuel Marque, Virginie Louvain, Claire Calmei, Elsa Bianchini, Martine Aiach